127 results on '"Dupont, Erik"'
Search Results
2. Heterozygous mutations in GTP-cyclohydrolase-1 reduce BH4 biosynthesis but not pain sensitivity
3. The natural history of multiple system atrophy: a prospective European cohort study
4. The Long-Acting Dopamine Receptor Agonist Cabergoline in Early Parkinson’s Disease: Final Results of a 5-Year, Double-Blind, Levodopa-Controlled Study
5. The risk of valvular regurgitation in patients with Parkinsonʼs disease treated with dopamine receptor agonists†
6. Red flags for multiple system atrophy
7. Genomic deletion size at the epsilon-sarcoglycan locus determines the clinical phenotype
8. Health-Related Quality of Life in Multiple System Atrophy
9. Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG)
10. UCHL-1 gene in multiple system atrophy: A haplotype tagging approach
11. Dopa-Responsive Dystonia and Tourette Syndrome in a Large Danish Family
12. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)
13. Heart abnormalities in Parkinson patients after discontinuation or continuation of ergot-derived dopamine agonists: a treatment-blinded echocardiographic study
14. Valvular heart disease associated with the treatment of Parkinson disease
15. Health-related Quality of Life in Multiple System Atrophy
16. Deep brain stimulation of therapy-refractory, disabling dystonia. Danish Society of Movement Disorders (Danmodis)
17. Tasmar®-en værdifuld medicin er igen i handelen til behandling af Parkinsons sygdom i Danmark og i det øvrige EU
18. Tandproblemer og mundhygiejne hos patienter med Parkinsons sygdom
19. Deep Brain Stimulation af behandlingsrefraktær, invaliderende dystoni
20. Påvirkning af hjerteklapperne? Patienter med Parkinsons sygdom i langtidsbehandling med Permax® og Cabaser®
21. Sygdomme i basalganglierne og andre bevægeforstyrrelser
22. Dopa-responsive dystonia and Tourette's syndrome in a large Danish family
23. A novel mutation in the -sarcoglycan gene causing myoclonus-dystonia syndrome
24. The surgical capacity for treatment of Parkinson disease with STN stimulation in Denmark
25. Parkinsons sygdom
26. Impaired Behavioural Pain Responses in hph-1 Mice with Inherited Deficiency in GTP Cyclohydrolase 1 in Models of Inflammatory Pain
27. Low somatostatin content in cerebrospinal fluid in multiple sclerosis
28. Reply
29. Dopaminergic agonist Ro 8-4650 in Parkinson's disease
30. Myoclonus‐dystonia due to genomic deletions in the epsilon‐sarcoglycan gene
31. Improvement of sleep quality in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus
32. Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations
33. Cabergoline plasma concentration is increased during concomitant treatment with itraconazole
34. Book review
35. Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry.
36. The hemodynamic effects of triglycyl‐lysine‐vasopressin (glypressin) in patients with parkinsonism and orthostatic hypotension
37. Ergotamine-derived dopamine agonists and left ventricular function in Parkinson patients: systolic and diastolic function studied by conventional echocardiography, tissue Doppler imaging, and two-dimensional speckle tracking.
38. The Long-Acting Dopamine Receptor Agonist Cabergoline in Early Parkinson’s Disease: Final Results of a 5-Year, Double-Blind, Levodopa-Controlled Study.
39. Nature and frequency of dental changes in idiopathic hypoparathyroidism and pseudohypoparathyroidism.
40. The effect of the GABA-agonist, progabide, on benign essential tremor.
41. Low somatostatin content in cerebrospinal fluid in multiple sclerosis.
42. PARKINSON'S DISEASE TREATED WITH SINEMET OR MADOPAR.
43. Tolcapone added to levodopa in stable parkinsonian patients: A double-blind placebo-controlled study.
44. Low cerebrospinal fluid somatostatin in Parkinson disease.
45. Dopaminergic agonist Ro 8-4650 in Parkinson's disease.
46. BROMOCRIPTINE INDUCED COLLAGENOSIS-LIKE SYMPTOMATOLOGY IN PARKINSON'S DISEASE
47. Madopar HBS: Slow-Release Levodopa and Benserazide in Parkinsonian Patients Presenting Marked Fluctuations in Symptoms on Standard L-Dopa Treatment
48. Bromocriptine and erythromelalgia‐like eruptions
49. Reply.
50. Bromocriptine and erythromelalgialike eruptions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.